Tranzyme Pharma and Norgine announced initiation of their Phase 3 study of ulimorelin for the treatment of postoperative ileus (POI). The objective is to evaluate the efficacy and safety of two once-daily dosage regimens of ulimorelin (160 and 480mcg/kg) in accelerating gastrointestinal recovery in patients undergoing partial bowel resection. The primary endpoint of the study is the time to GI recovery defined as the time to the latest of first bowel movement and first intake of solid food.

Ulimorelin is an intravenous, promotility ghrelin agonist currently in clinical development for the management of POI in acute care settings. 

For more information call (919) 313-4760 or visit www.tranzyme.com.